Characterization of carbamazepine metabolism in a mouse model of carbamazepine teratogenicity

Drug Metabolism and Disposition

Volumn 25, Issue 8, 1997, Pages 953-962

  Amore, Benny M ^b   Kalhorn, Thomas F ^b   Skiles, Gary L ^b   Hunter, Ann P ^b   Bennett, Greg D ^b   Finnell, Richard H ^b   Nelson, Sidney D ^b   Slattery, John T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CARBON 14; DRUG METABOLITE; PHENOBARBITAL; STIRIPENTOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG URINE LEVEL; EPILEPSY; FECES LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; TERATOGENICITY;

ANIMALS; CARBAMAZEPINE; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED STRAINS; TERATOGENS;

ANIMALIA;

EID: 0030812306     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. M. Sanders: Epilepsy in women of childbearing age. Br. Med. J. 299, 581-582 (1989).
2. C. Morrison and M. J. Rieder: Practices of epilepsy during pregnancy: a survey of Canadian neurologists. Reprod. Toxicol. 7, 559 (1993).
3. D. Lindhout, R. J. E. A. Hoppener, and H. Meinardi: Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation of carbamazepine. Epilepsia 25, 77-83 (1984).
4. S. Kaneko, K. Otani, Y. Fukushima, Y. Ogawa, Y. Nomura, T. Ono, Y. Makane, T. Teranishi, and M. Goto: Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29, 459-467 (1988).
5. S. Kaneko, K. Otani, T. Kondo, Y. Fukushim, Y. Nakamura, Y. Ogawa, R. Kan, A. Takeda, Y. Nakane, and T. Teranishi: Malformation in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 42 (Suppl. 5), 68-74 (1992).
6. K. L. Jones, R. V. Larco, K. A. Johnson, and J. Adams: Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N. Engl. J. Med. 320, 1661-1666 (1989).
7. L. V. Dansky and R. H. Finnell: Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiological and experimental findings spanning three decades. II. Human studies. Reprod. Toxicol. 5, 301-335 (1991).
8. Y. Nakane, T. Okuma, T. Takahashi, Y. Sato, T. Wada, T. Sato, Y. Fukushima, H. Kumashiro, T. Ono, T. Takahashi, Y. Aoki, H. Kazamatsuri, M. Inami, S. Komai, M. Seino, M. Miyakoshi, T. Tanimura, H. Hazama, R. Kawahara, S. Otsuki, K. Hosokawa, K. Inanaga, Y. Nakazawa, and K. Yamamoto: Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: report of a collaborative study group in Japan. Epilepsia 21, 663-680 (1980).
9. J. G. C. Omtzigt, F. J. Los, J. W. A. Meijer, and D. Lindhout: The 10,11-epoxide-10.11-diol pathway of carbamazepine in early pregnancy in maternal serum, urine, and amniotic fluid: effect of dose, comedication, and relation to outcome of pregnancy. Ther. Drug Monit. 15, 1-10 (1993).
10. M. Eichelbaum, T. Tomson, G. Tybing, and L. Bertilsson: Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin. Pharmacokinet. 10, 80-90 (1985).
11. J. W. Faigle and K. F. Feldmann: Carbamazepine. Chemistry and biotransformation. In "Antiepileptic Drugs" (R. H. Levy, R. H. Mattson, and B. S. Meldrum, eds.), pp. 499-513. Raven Press Ltd., New York, 1995.
12. K. Lertratanangkoon and M. G. Horning: Metabolism of carbamazepine. Drug Metab. Dispos. 10, 1-10 (1982).
13. R. H. Finnell, G. D. Bennett, J. T. Slattery, B. M. Amore, M. Bajpai, and R. H. Levy: Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 52, 324-332 (1995).
14. M. Mesnil, B. Testa, and P. Jenner: Ex vivo inhibition of rat brain cytochrome P-450 activity by stiripentol. Biochem. Pharmacol. 37, 3619-3622 (1988).
15. S. M. Furst and J. P. Uetrecht: Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol. 45, 1267-1275 (1993).
16. B. M. Kerr and R. H. Levy: Carbamazepine. Carbamazepine epoxide. In "Antiepileptic Drugs" (R. H. Levy, R. H. Mattson, and B. S. Meldrum, eds.), pp. 529-541. Raven Press Ltd., New York, 1995.
17. G. D. Bennett, B. M. Amore, R. H. Finnell, B. Wlodarczyk, T. F. Kalhorn, G. L. Skiles, S. D. Nelson, and J. T. Slattery: Teratogenicity of carbamazepine-10,11-epoxide and oxcarbazepine in the SWV mouse. J. Pharmacol. Exp. Ther. 279, 1237-1242 (1997).
18. H. Jeffey and J. Alvarez: Liquid scintillation counting of carbon-14. Use of ethanolamine-ethylene glycol monoethyl ether-toluene. Anal. Chem. 33, 612-615 (1961).
19. D. J. Porubek, M. P. Grillo, and T. A. Baillie: The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentanoic acid, in rats and in isolated rat hepatocytes. Drug Metab. Dispos. 17, 123-130 (1989).
20. R. H. Finnell, V. K. Mohi, G. D. Bennett, and S. M. Taylor: Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. Teratogenesis Carcinog. Mutagen 6, 393-401 (1986).
21. R. H. Finnell, B. A. Buehler, B. M. Kerr, P. L. Ager, and R. H. Levy: Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 42, 25-31 (1992).
22. C. Fenselau: Tandem mass spectrometry: the competitive edge for pharmacology. Annu. Rev. Pharmacol. Toxicol. 32, 355-378 (1992).
23. A. Frigerio, R. Fanelli, P. Biandrate, G. Passerini, P. L. Morselli, and S. Garattini: Mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine. J. Pharm. Sci. 61, 1144-1147 (1972).
24. H. Kutt and H. Paris-Kutt: Carbamazepine. Chemistry and methods of determination. In "Antiepileptic Drugs" (D. M. Woodbury, J. K. Penry, and C. E. Pippenger, eds.), pp. 453-463. Raven Press Ltd., New York, 1982.
25. S. Madde, J. L. Maggs, and B. K. Park: Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). Drug Metab. Dispos. 24, 469-479 (1996).
26. F. W. McLafferty and F. Turecek: "Interpretation of Mass Spectra." University Science Books, Mill Valley, CA, 1993.
27. D. Jovanovic: Mass spectrometry of dibenzoazepines and 10,11-dihydrodibenzoazepines. Adv. Mass Spec. 6, 61-67 (1974).
28. K. H. Beyer and G. Spiteller: A new carbamazepine metabolite in uraemic filtrate. Xenobiotica 22, 1029-1035 (1992).
29. K. M. Baker, A. Frigerio, P. L. Morselli, and G. Pifferi: Identification of a rearranged degradation product from carbamazepine-10,11-epoxide. J. Pharm. Sci. 62, 475-476 (1973).
30. J. L. Lillibridge, B. M. Amore, J. T. Slattery, T. F. Kalhorn, S. D. Nelson, R. H. Finnell, and G. D. Bennett: Protein-reactive metabolites of carbamazepine in mouse liver microsomes. Drug Metab. Dispos. 24, 509-514 (1996).
31. R. J. Riley, N. R. Kitteringham, and B. K. Park: Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br. J. Clin. Pharmacol. 28, 482-487 (1989).
32. M. Pirmohamed, N. R. Kitteringham, T. M. Guenthner, A. M. Breckenridge, and B. K. Park: An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 43, 1675-1682 (1992).
33. J. E. Bakke, C. Struble, J. A. Gustafsson, and B. Gustafsson: Catabolism of premercapturic acid pathway metabolites of naphthalene to naphthols and methylthio-containing metabolites in rats. Proc. Natl. Acad. Sci. U.S.A. 82, 668-671 (1985).
34. K. Lertratanangkoon: O- and S-methylated bromothiocatechols. Toxicol. Appl. Pharmacol. 122, 200-207 (1993).
35. S. Suzuki and M. Tateishi: Purification and characterization of a rat liver enzyme catalyzing N-deacetylation of mercapturic acid conjugates. Drug Merab. Dispos. 9, 573-577 (1981).
36. M. Tateishi and H. Shimizu: Cysteine conjugate β-lyase. In "Enzymatic Basis of Detoxification" (W. Jakoby, ed.), vol. II, pp. 121-130. Academic Press, New York, 1980.
37. M. Tateishi: Methylthiolated metabolites. Drug Metab. Rev. 14, 1207-1234 (1983).
38. J. E. Bakke: Biochemical and physiological dispositions of glutathione conjugates. Drug Metab. Rev. 22, 6-8 (1990).
39. N. H. Shear and S. P. Spielberg: Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J. Clin. Invest. 82, 1826-1832 (1988).
40. D. Lindhoul: Pharmacogenetics and drug interactions: role in antiepileptic-drug-induced teratogenesis. Neurology 42 (Suppl. 5), 43-47 (1992).
41. A. Gaedigk, S. P. Spielberg, and D. M. Grant: Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4, 142-153 (1994).
42. V. J. Green, M. Pirmohamed, N. R. Kitteringham, A. Gaedigk, D. M. Grant, M. Boxer, B. Burchell, and B. K. Park: Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem. Pharmacol. 50, 1353-1359 (1995).
43. J. Jonsson, H. Rodriguez-Martinez, and I. Brandt: Transplacental toxicity of 3-methylsuphonyl-DDE in the developing adrenal cortex in mice. Reprod. Toxicol. 9, 257-264 (1995).